Handelsbanken Fonder AB Cuts Stock Position in Immunome, Inc. (NASDAQ:IMNM)

Handelsbanken Fonder AB trimmed its stake in shares of Immunome, Inc. (NASDAQ:IMNM) by 13.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 200,000 shares of the company’s stock after selling 30,000 shares during the period. Handelsbanken Fonder AB’s holdings in Immunome were worth $2,124,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of IMNM. FMR LLC boosted its stake in shares of Immunome by 0.3% in the third quarter. FMR LLC now owns 4,224,700 shares of the company’s stock worth $61,765,000 after acquiring an additional 13,757 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in Immunome by 10.3% in the 3rd quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company’s stock valued at $50,971,000 after purchasing an additional 324,614 shares in the last quarter. Geode Capital Management LLC boosted its stake in Immunome by 13.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,207,455 shares of the company’s stock worth $17,657,000 after purchasing an additional 144,557 shares during the last quarter. Victory Capital Management Inc. grew its holdings in shares of Immunome by 48.1% during the third quarter. Victory Capital Management Inc. now owns 730,785 shares of the company’s stock worth $10,684,000 after buying an additional 237,497 shares in the last quarter. Finally, Point72 Asset Management L.P. grew its holdings in shares of Immunome by 22.2% during the third quarter. Point72 Asset Management L.P. now owns 470,647 shares of the company’s stock worth $6,881,000 after buying an additional 85,580 shares in the last quarter. Institutional investors and hedge funds own 44.58% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on IMNM. Stephens assumed coverage on shares of Immunome in a research note on Friday, November 8th. They issued an “overweight” rating and a $30.00 price target on the stock. Piper Sandler decreased their target price on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating on the stock in a research note on Thursday, November 14th. Finally, Wedbush restated an “outperform” rating and set a $33.00 target price on shares of Immunome in a report on Monday, January 13th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $28.60.

Insider Buying and Selling at Immunome

In other news, CEO Clay B. Siegall purchased 150,000 shares of the business’s stock in a transaction dated Friday, January 31st. The stock was acquired at an average price of $7.75 per share, for a total transaction of $1,162,500.00. Following the acquisition, the chief executive officer now directly owns 669,636 shares of the company’s stock, valued at approximately $5,189,679. This represents a 28.87 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 8.60% of the stock is currently owned by company insiders.

Immunome Trading Up 3.4 %

Shares of IMNM stock opened at $9.67 on Wednesday. Immunome, Inc. has a twelve month low of $8.93 and a twelve month high of $30.96. The stock has a market cap of $771.44 million, a price-to-earnings ratio of -1.19 and a beta of 1.90. The company’s 50-day moving average price is $10.44 and its 200-day moving average price is $12.25.

Immunome Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.